You are here
SIGNABLOK, INC.
UEI: JM5UN38YM1H7
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
First-in-class TREM-1 inhibitors for neovascular retinal diseases
Amount: $278,127.00Project Summary/Abstract Retinal neovascularization (RNV) is a major cause of vision loss in retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion. In the US, about 16 ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
Amount: $272,741.00Project Summary/Abstract Every year, 150,000 Americans are affected by Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition that may complicate severe pneumonia (including influe ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
TREM-1 therapy for rheumatoid arthritis
Amount: $258,603.00Project Summary/Abstract Rheumatoid arthritis (RA), a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints, affects about 1.5 million Americans and costs society more ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
TREM-1 inhibitor for the treatment of scleroderma
Amount: $249,601.00Project Summary/Abstract Scleroderma that includes localized scleroderma (LS) and systemic sclerosis (SSc) is a rare but devastating autoimmune disorder. Current therapies all have side effects, are l ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
First-in-class TREM-1 Radioprotector to Prevent the Effects of Acute Radiation Syndrome
Amount: $220,006.00Problem. No FDA-approved prophylactic Medical Counter Measures (MCMs) are currently available for Ionizing Radiation (IR) exposures that result in Acute Radiation Syndrome (ARS), suggesting an unmet n ...
SBIRPhase I2020Department of Defense Defense Health Agency -
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Amount: $1,997,806.00Project Summary/Abstract Carcinoma of the pancreas, or pancreatic cancer (PC), is the third leading cause of cancer-related death in the US. Despite recent advances in the current treatments that incl ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases
Amount: $226,223.00Project Summary Abstract Retinal neovascularizationRNVis a determinant cause of vision loss in retinopathy of prematurityROPdiabetic retinopathyDRand retinal vein occlusionRVOIn the USaboutof prematur ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Novel TREM-1 targeting therapies for sepsis
Amount: $224,996.00Project Summary Abstract Sepsis kills more thanAmericans annuallyNo approved drugs are available and overdrug candidates failed late stage clinical trialswhich highlights the urgent need for novel app ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Amount: $226,756.00Project Summary Abstract Carcinoma of the pancreasor pancreatic cancerPCis the fourth leading cause of cancer related death in the United StatesAccording to the American Cancer Societynew cases are ex ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Treatment of alcoholic liver disease with novel targeted inhibitors
Amount: $223,443.00DESCRIPTION provided by applicant Alcoholic liver disease ALD affects millions of people globally and often leads to fibrosis and cirrhosis With a total of deaths in of which we ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health
